{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:empatica-q96377245-answer-090fbb541723fd9fcb23","key":"buyer_question:empatica-q96377245-answer-090fbb541723fd9fcb23","kind":"buyer_question","slug":"empatica-q96377245-answer-090fbb541723fd9fcb23","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/empatica-q96377245-answer-090fbb541723fd9fcb23","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/empatica-q96377245-answer-090fbb541723fd9fcb23.json","datePublished":"2026-10-20","dateModified":"2026-10-20","materialFingerprint":"fnv1a64:f48cf49938f0363a","membershipFingerprint":"fnv1a64:95b90b4401daaca7","relatedEntitySlugs":["empatica-q96377245"],"relatedSurfaceKeys":["buyer_question:empatica-q96377245-answer-1a81380a87b94f4a0751","buyer_question:empatica-q96377245-answer-9d72adfa6e6751c73069","buyer_question:empatica-q96377245-answer-df80e574bdebcaa44522","evidence:empatica-q96377245"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"empatica-q96377245-content-3d82b586f89ce3dd-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q96377245","sourceRevisionId":"Q96377245:content:ee3b995e5ece7b94","sourceContentHash":"fnv1a64:7faaaa2a22f5a2fe","recordRevisionId":"Q96377245:content:ee3b995e5ece7b94","recordContentHash":"fnv1a64:d1add356c2a8a2d7","sourceCanonicalUrl":"https://www.empatica.com/","sourceModifiedAt":"2026-10-20T16:05:25.899Z","observedOn":"2026-10-20","permission":{"basis":"public_information","evidenceUrl":"https://www.empatica.com/"},"attributionUrl":"https://www.empatica.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"Who uses Empatica?","summary":"Cited source answers across 1 active corpus record.","question":"Who uses Empatica?","answers":[{"entitySlug":"empatica-q96377245","entityName":"Empatica","answer":"“Researchers, clinicians, pharmaceutical companies and CROs. More than half of the top 20 pharmaceutical companies use the Empatica Health Monitoring Platform to monitor treatment impact and develop novel digital biomarkers as digital endpoints.”","sourceUrls":["https://www.empatica.com/"]}]}